Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial
Background Neoadjuvant systemic therapy (NST) for triple-negative breast cancer and
HER2-positive breast cancer yields a pathological complete response in approximately 60 …
HER2-positive breast cancer yields a pathological complete response in approximately 60 …
Nonoperative management for invasive breast cancer after neoadjuvant systemic therapy: conceptual basis and fundamental international feasibility clinical trials
With current advances in neoadjuvant systemic therapy (NST) and improved breast imaging,
the potential of nonoperative therapy for invasive breast cancer has emerged as a viable …
the potential of nonoperative therapy for invasive breast cancer has emerged as a viable …
A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy
HM Kuerer, GM Rauch, S Krishnamurthy… - Annals of …, 2018 - journals.lww.com
Objective: To determine the accuracy of fine-needle aspiration (FNA) and vacuum-assisted
core biopsy (VACB) in assessing the presence of residual cancer in the breast after …
core biopsy (VACB) in assessing the presence of residual cancer in the breast after …
[HTML][HTML] Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges
Highlights•Safe past de-escalation treatments.•Surgery after complete response might be
overtreatment.•Biopsies might diagnose response.In patients with operable early breast …
overtreatment.•Biopsies might diagnose response.In patients with operable early breast …
Diagnosing pathologic complete response in the breast after neoadjuvant systemic treatment of breast cancer patients by minimal invasive biopsy: oral presentation at …
Objective: We evaluated the ability of minimally invasive, image-guided vacuum-assisted
biopsy (VAB) to reliably diagnose a pathologic complete response in the breast (pCR-B) …
biopsy (VAB) to reliably diagnose a pathologic complete response in the breast (pCR-B) …
Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit
PER Spronk, JH Volders, P van den Tol… - European Journal of …, 2019 - Elsevier
Introduction NAC has led to an increase in breast conserving surgery (BCS) worldwide. This
study aims to analyse trends in the use of neoadjuvant chemotherapy (NAC) and the impact …
study aims to analyse trends in the use of neoadjuvant chemotherapy (NAC) and the impact …
Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial
Importance Neoadjuvant systemic therapy (NST) is often administered to enable breast-
conserving therapy (BCT) in stages II to III breast cancer. Objectives To prospectively …
conserving therapy (BCT) in stages II to III breast cancer. Objectives To prospectively …
Neoadjuvant chemotherapy in breast cancer: more than just downsizing
MGM Derks, CJH van de Velde - The Lancet Oncology, 2018 - thelancet.com
The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) has established a new
milestone in evidencebased treatment for early breast cancer. Through longstanding …
milestone in evidencebased treatment for early breast cancer. Through longstanding …
Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery
AB Tadros, WT Yang, S Krishnamurthy… - JAMA …, 2017 - jamanetwork.com
Importance A pathologic complete response (pCR; no invasive or in situ cancer) occurs in
40% to 50% of patients withHER2-positive (HER2+) and triple-negative (TN) breast cancer …
40% to 50% of patients withHER2-positive (HER2+) and triple-negative (TN) breast cancer …
[HTML][HTML] Minimally invasive complete response assessment of the breast after neoadjuvant systemic therapy for early breast cancer (MICRA trial): interim analysis of a …
AA van Loevezijn, MEM van der Noordaa… - Annals of surgical …, 2021 - Springer
Background The added value of surgery in breast cancer patients with pathological
complete response (pCR) after neoadjuvant systemic therapy (NST) is uncertain. The …
complete response (pCR) after neoadjuvant systemic therapy (NST) is uncertain. The …